São Paulo Confirms Limited Mounjaro Use, Rejects Link to Injury Surge

Overview

• The club said two first-team players received tirzepatide after clinical assessment under specialist oversight, with reports attributing the prescriptions to physician Eduardo Rauen.
• São Paulo denied any causal connection to the rise in injuries and emphasized the drug was used only in punctual, individualized cases, not broadly across the squad.
• The team stated the treatment complied with Brazilian rules, noting Mounjaro is authorized by Anvisa and produced by Eli Lilly, with prescriptions issued under ethical and legal protocols.
• Media counts reported 24 of 33 players had injuries or medical-department visits in 2025, intensifying scrutiny of the club’s health management.
• Sports-medicine experts warned that reduced appetite and potential lean-mass loss from tirzepatide can impair strength and recovery and raise injury risk without rigorous monitoring.